DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Takes Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 303,479 shares of the company's stock, valued at approximately $5,083,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main owned 0.23% of Centessa Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC raised its holdings in Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after acquiring an additional 865 shares in the last quarter. Barclays PLC grew its stake in shares of Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after buying an additional 4,952 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in Centessa Pharmaceuticals during the fourth quarter worth $162,000. China Universal Asset Management Co. Ltd. increased its holdings in Centessa Pharmaceuticals by 39.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock worth $317,000 after buying an additional 5,316 shares during the last quarter. Finally, Ameriprise Financial Inc. bought a new stake in Centessa Pharmaceuticals during the fourth quarter worth $320,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, General Counsel Iqbal J. Hussain sold 2,080 shares of the stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $14.01, for a total transaction of $29,140.80. Following the completion of the transaction, the general counsel now directly owns 105,386 shares of the company's stock, valued at $1,476,457.86. This represents a 1.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00. Following the completion of the sale, the chief executive officer now directly owns 331,017 shares in the company, valued at $5,273,100.81. This trade represents a 14.25% decrease in their position. The disclosure for this sale can be found here. Insiders sold 171,398 shares of company stock worth $2,697,422 in the last quarter. 11.59% of the stock is currently owned by company insiders.

Centessa Pharmaceuticals Stock Down 5.2%

CNTA stock traded down $0.69 during mid-day trading on Tuesday, reaching $12.46. 492,693 shares of the company traded hands, compared to its average volume of 627,186. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm's 50 day moving average price is $13.79 and its 200 day moving average price is $15.66. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -8.14 and a beta of 1.53. Centessa Pharmaceuticals plc has a fifty-two week low of $7.75 and a fifty-two week high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.04. As a group, equities research analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CNTA has been the topic of a number of recent analyst reports. Guggenheim reissued a "buy" rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an "overweight" rating and a $38.00 price objective for the company. Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued an "outperform" rating and a $6.00 price objective on the stock. Chardan Capital initiated coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They set a "buy" rating and a $30.00 target price for the company. Finally, Morgan Stanley reissued an "overweight" rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $27.00.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.